Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 27

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 27
---
 extent to which we enter into additional
collaboration arrangements regarding product discovery or development;

·the costs, timing and outcome of regulatory review
of product candidates;

·our ability to establish additional collaborations
with favorable terms, if at all;

·the costs of future commercialization activities,
including product sales, marketing, manufacturing and distribution, for any of product candidates for which we receive marketing approval;

·the costs of preparing, filing and prosecuting
patent applications, maintaining and enforcing any potential intellectual property rights and defending any potential intellectual property-related
claims;

·the costs to in-license technology for new products
or technologies; and

·revenue, if any, received from commercial sales
of product candidates, should any product candidates receive marketing approval.

Identifying potential product candidates and conducting
manufacturing and process development, preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, any product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be
derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need
to continue to rely on additional financing to achieve our business objectives. Adequate additional capital is unlikely to be available
on favorable terms or at all.

Raising capital will cause dilution to our stockholders,
restrict our operations, or require us to relinquish rights to our technologies or product candidates. 

Until such time, if ever, as we can generate substantial
product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, and/or licensing arrangements.
While we do not have any committed external source of funds, if we raise funds from the issuance of equity securities (which will be challenging
in light of current market conditions), substantial dilution to our existing stockholders would likely result. If we raise additional
funds by incurring debt financing (also challenging in light of current market conditions combined), the terms of the debt may involve
significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

We cannot be certain that additional funding will
be available on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may be required to cease our operations
altogether.

 16 

Because